Compugen Ltd. CGEN announced today the signing of a collaboration
and license agreement for the research, development, and commercialization of
antibody-based therapeutics for cancer immunotherapy against two novel
Compugen discovered immune checkpoint regulators. Under the terms of the
agreement, Bayer HealthCare (Bayer) and Compugen will jointly pursue a
preclinical research program. Subsequently, Bayer will have full control over
further development and have worldwide commercialization rights for potential
cancer therapeutics.
Under the agreement Compugen will receive an upfront payment of USD 10
million, and is eligible to receive over USD 500 million in potential
milestone payments for both programs, not including milestone payments of up
to USD 30 million associated with preclinical activities. Additionally,
Compugen is also eligible to receive mid to high single digit royalties on
global net sales of any resulting products under the collaboration.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in